Peffley D M, Gayen A K
Department of Pharmacology and Molecular Biology, Finch University of Health Sciences, Chicago Medical School, Illinois 60064, USA.
Somat Cell Mol Genet. 1995 May;21(3):189-204. doi: 10.1007/BF02254770.
We reported previously that 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis is regulated at the translational level by mevalonate. To determine at what stage mevalonate affects reductase synthesis, we examined the distribution of reductase mRNA in polysomes from cells treated with lovastatin alone; lovastatin and 25-hydroxycholesterol; or lovastatin, 25-hydroxycholesterol, and mevalonate. In lovastatin-treated cells, reductase mRNA was primarily associated with heavy polysome fractions. When 25-hydroxycholesterol was added to lovastatin-treated cells, reductase mRNA levels were reduced approximately fourfold in all polysome fractions, with no accompanying redistribution of reductase mRNA into lighter polysome fractions. However, addition of both 25-hydroxycholesterol and mevalonate to lovastatin-treated cells shifted reductase mRNA from heavier to lighter polysome fractions. No change in the distribution of control beta-actin or ribosomal protein S17 mRNA occurred with any of the treatments. These results suggest that mevalonate suppresses reductase synthesis at the level of initiation. When the translation inhibitor cycloheximide was added to all three regimens, reductase mRNA shifted into heavy polysome fractions. Treatment with either lovastatin alone or lovastatin plus 25-hydroxycholesterol resulted in a 50% greater loss of reductase mRNA from the heavy polysome fractions compared to the same fractions from noncycloheximide-treated cells. No loss of reductase mRNA occurred when cycloheximide was added to cells treated with both 25-hydroxycholesterol and mevalonate. beta-Actin mRNA levels and polysome distribution were not significantly changed by cycloheximide under any of these conditions. Translationally mediated suppression of reductase mRNA did not occur when protein synthesis was inhibited with puromycin. Our results indicate that regulation of reductase mRNA levels is translation-dependent and is linked to the rate of elongation.
我们之前报道过,3-羟基-3-甲基戊二酰辅酶A还原酶的合成在翻译水平上受甲羟戊酸调控。为了确定甲羟戊酸在哪个阶段影响还原酶的合成,我们检测了单独用洛伐他汀处理的细胞、用洛伐他汀和25-羟基胆固醇处理的细胞以及用洛伐他汀、25-羟基胆固醇和甲羟戊酸处理的细胞中多核糖体上还原酶mRNA的分布情况。在用洛伐他汀处理的细胞中,还原酶mRNA主要与重多核糖体组分相关。当向用洛伐他汀处理的细胞中添加25-羟基胆固醇时,所有多核糖体组分中的还原酶mRNA水平大约降低了四倍,且还原酶mRNA没有伴随重新分布到较轻的多核糖体组分中。然而,向用洛伐他汀处理的细胞中同时添加25-羟基胆固醇和甲羟戊酸会使还原酶mRNA从重多核糖体组分转移到较轻的多核糖体组分中。任何一种处理对对照β-肌动蛋白或核糖体蛋白S17 mRNA的分布都没有影响。这些结果表明,甲羟戊酸在起始水平抑制还原酶的合成。当将翻译抑制剂环己酰亚胺添加到所有三种处理方案中时,还原酶mRNA转移到了重多核糖体组分中。与未用环己酰亚胺处理的细胞的相同组分相比,单独用洛伐他汀或用洛伐他汀加25-羟基胆固醇处理导致从重多核糖体组分中损失的还原酶mRNA多50%。当向用25-羟基胆固醇和甲羟戊酸处理的细胞中添加环己酰亚胺时,没有还原酶mRNA的损失。在任何这些条件下,环己酰亚胺对β-肌动蛋白mRNA水平和多核糖体分布都没有显著影响。当用嘌呤霉素抑制蛋白质合成时,未发生翻译介导的还原酶mRNA抑制。我们的结果表明,还原酶mRNA水平的调控是翻译依赖性的,并且与延伸速率相关。